- Home
- CYCC vs PASG Comparison
CYCC vs PASG Comparison
Compare CYCC & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- PASG
- Stock Information
- Founded
- CYCC 1992
- PASG 2017
- Country
- CYCC Malaysia
- PASG United States
- Employees
- CYCC N/A
- PASG N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- CYCC Health Care
- PASG Health Care
- Exchange
- CYCC Nasdaq
- PASG Nasdaq
- Market Cap
- CYCC 17.5M
- PASG 20.3M
- IPO Year
- CYCC N/A
- PASG 2020
- Fundamental
- Price
- CYCC $6.37
- PASG $7.00
- Analyst Decision
- CYCC
- PASG Strong Buy
- Analyst Count
- CYCC 0
- PASG 4
- Target Price
- CYCC N/A
- PASG $59.25
- AVG Volume (30 Days)
- CYCC 82.6K
- PASG 35.5K
- Earning Date
- CYCC 11-11-2025
- PASG 11-12-2025
- Dividend Yield
- CYCC N/A
- PASG N/A
- EPS Growth
- CYCC N/A
- PASG N/A
- EPS
- CYCC N/A
- PASG N/A
- Revenue
- CYCC $10,000.00
- PASG N/A
- Revenue This Year
- CYCC $137.21
- PASG N/A
- Revenue Next Year
- CYCC N/A
- PASG N/A
- P/E Ratio
- CYCC N/A
- PASG N/A
- Revenue Growth
- CYCC N/A
- PASG N/A
- 52 Week Low
- CYCC $3.08
- PASG $5.12
- 52 Week High
- CYCC $597.60
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- CYCC 37.28
- PASG 50.90
- Support Level
- CYCC $5.92
- PASG $6.86
- Resistance Level
- CYCC $8.82
- PASG $7.29
- Average True Range (ATR)
- CYCC 0.58
- PASG 0.47
- MACD
- CYCC -0.04
- PASG -0.03
- Stochastic Oscillator
- CYCC 15.52
- PASG 34.58
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.